Urinary NMP22® BladderChek® Test in the Diagnosis of Superficial Bladder Cancer

Moonen, Paula M.J.; Kiemeney, Lambertus A.; Witjes, J. Alfred

doi:10.1016/j.eururo.2005.09.002

Cited by 55 publications

(31 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The NMP22 test uses nuclear matrix protein, a specific nuclear protein that is responsible for the chromatid regulation and cell separation during replication in voided urine (Moonen et al, 2005). Two NMP22 tests are available for daily practice.…”

Section: Discussionmentioning

confidence: 99%

Identification of Patients with Microscopic Hematuria who are at Greater Risk for the Presence of Bladder Tumors Using a Dedicated Questionnaire and Point of Care Urine Test - A Study by the Members of Association of Urooncology, Turkey

Türkeri

Mangır²,

Günlüsoy³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Asian Pac J Cancer Prev, 15 (15), 6283-6286 IntroductionMicroscpic hematuria is a common incidental finding and its prevalence is between 9 to 20% in apparently normal population and defined by the American Urologic Association (AUA) best practice guidelines as 3 or more red blood cells per high power field on microscopic examination of a properly collected urine specimen in the absence of any obvious benign cause (Grossfeld et al., 2001;Davis et al., 2012). It may be due to a multitude of urological problems however urothelial carcinoma of the bladder (UC) is probably the most significant one which is a major health problem across the world. Although not all patients are at the same risk for UC, approximately 3 % of male patients above the age of 40 with microscopic

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of Patients with Microscopic Hematuria who are at Greater Risk for the Presence of Bladder Tumors Using a Dedicated Questionnaire and Point of Care Urine Test - A Study by the Members of Association of Urooncology, Turkey

Türkeri

Mangır²,

Günlüsoy³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…[52][53][54][55][56][57][58][59][60][61][62][63] For example, for the marker NMP22, sensitivities ranged from 6.0-100% and specificities from 62-92%. With BTA-stat, specificities were reported in the range of 69-73%; and in studies investigating UroVysion FISH, sensitivities ranged from 61-100% and specificities from 71.4-93%.…”

Section: Discussionmentioning

confidence: 99%

Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015

Kassouf

Aprikian

Black

et al. 2016

CUAJ

View full text Add to dashboard Cite

This initiative was undertaken in response to concerns regarding the variation in management and in outcomes of patients with bladder cancer throughout centres and geographical areas in Canada. Population-based data have also revealed that real-life survival is lower than expected based on data from clinical trials and/or academic centres. To address these perceived shortcomings and attempt to streamline and unify treatment approaches to bladder cancer in Canada, a multidisciplinary panel of expert clinicians was convened last fall for a two-day working group consensus meeting. The panelists included urologic oncologists, medical oncologists, radiation oncologists, patient representatives, a genitourinary pathologist, and an enterostomal therapy nurse. The following recommendations and summaries of supporting evidence represent the results of the presentations, debates, and discussions. Methodology

show abstract

“…Specificity of the Bladder Cancer Test is reported to be 60.0%-95.0%, and specificity of the NMP22 BladderChek is reportedly in the range of 40.0%-89.8%. 11,[19][20][21][22][23]25,26,32,34,36,37,[39][40][41][42] The NMP22 tests are based on the release of NMPs into the urine following apoptosis of the urothelial cells, a process that can also occur as a result of benign conditions. As is the case with the BTA tests, NMP22 levels are raised in patients with urinary tract infections, concurrent urolithiasis, history of bladder interposition, other malignancies, intravesical therapies and even cystoscopy, all of which may contribute to false-positive results.…”

Section: Nuclear Matrix Protein 22mentioning

confidence: 99%

Biomarkers for detection and surveillance of bladder cancer

Budman

Kassouf

Steinberg

2013

CUAJ

126

View full text Add to dashboard Cite

Introduction: Bladder cancer is the fourth most common cancer in men and the ninth most common cancer in women in Canada. Early detection of tumours is essential for improved prognosis and long-term survival. The standard method for detection and surveillance is cystoscopy together with urine cytology. Cystoscopy is relatively sensitive but is expensive and invasive. Urinary cytology is a noninvasive method that has poor sensitivity but high specificity; it is relied on for the detection of carcinoma in situ. Currently, several urinary based bladder tumour biomarkers with USFDA/Health Canada approval are available commercially, but none have been widely adopted by urologists despite their offering high sensitivity and/or specificity. We present here a review of recent studies evaluating 7 commercial biomarker assays for the detection and/or surveillance of bladder cancer.Results: Sensitivity and specificity ranges, respectively, for each marker were reported as follows: BTA Stat (Polymedco), 52.5%–78.0% and 69.0%–87.1%; BTA Trak (Polymedco), 51%–100% and 73%–92.5%; cytology, 12.1%–84.6% and 78.0%–100%; hematuria dipstick, 47.0%–92.6% and 51.0%–84.0%; NMP22 Bladder Cancer Test (Matritech), 34.6%–100% and 60.0%–95.0%; NMP22 BladderChek (Matritech), 49.5%–65.0% and 40.0%–89.8%;ImmunoCyt/uCyt+ (DiagnoCure), 63.3%–84.9% and 62.0%–78.1%; ImmunoCyt/uCyt+ and cytology, 81.0%–89.3% and 61.0%–77.7%; and UroVysion (Abbott Molecular)/florescence in situ hybridization, 68.6%–100% and 65.0%–96.0%.Conclusion: We find that no currently available bladder cancer urinary marker is sensitive enough to eliminate the need for cystoscopy. In addition, cytology remains integral to the detection of occult cancer. However, owing to their relatively high sensitivities, these markers may be used to extend the period between cystoscopies in the surveillance of patients with transitional cell carcinoma. Further study is required to determine which markers, alone or in panel, would best accomplish this.

show abstract

Urinary NMP22® BladderChek® Test in the Diagnosis of Superficial Bladder Cancer

Cited by 55 publications

References 17 publications

Identification of Patients with Microscopic Hematuria who are at Greater Risk for the Presence of Bladder Tumors Using a Dedicated Questionnaire and Point of Care Urine Test - A Study by the Members of Association of Urooncology, Turkey

Identification of Patients with Microscopic Hematuria who are at Greater Risk for the Presence of Bladder Tumors Using a Dedicated Questionnaire and Point of Care Urine Test - A Study by the Members of Association of Urooncology, Turkey

Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015

Biomarkers for detection and surveillance of bladder cancer

Contact Info

Product

Resources

About